Clinical Trials Browser

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT02726997 2025-12-18

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Phase 1/2 Active not recruiting

18 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT06710548 2025-12-17

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Phase NA Recruiting

240 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07265739 2025-12-11

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Phase 2 Not yet recruiting

27 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Phase 3 Completed

143 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

NCT02068794 2025-11-18

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 1/2 Active not recruiting

34 enrolled 12 charts

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06342986 2025-11-12

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Recruiting

33 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05287451 2025-11-05

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Phase NA Recruiting

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02111941 2025-10-31

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase EARLY_PHASE1 Completed

19 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06617923 2025-10-27

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Phase 2 Recruiting

18 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03325634 2025-10-23

Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer

Phase 1 Completed

15 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03188432 2025-10-21

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

50 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02659241 2025-10-14

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase EARLY_PHASE1 Active not recruiting

38 enrolled

Gynecologic

Carcinoma, Fallopian Tube Neoplasms

NCT03604315 2025-10-14

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Phase 1 Recruiting

300 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03355976 2025-10-09

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT03026062 2025-09-19

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03029403 2025-09-19

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2 Active not recruiting

47 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06451263 2025-09-19

Nudge to Gynecologic Oncology

Phase NA Active not recruiting

20 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04387227 2025-09-18

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

22 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

970 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05708924 2025-08-14

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Terminated

1 enrolled 5 charts

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

TILsOV

BCB-OVAIRE

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

PROOV

Depression Treatment and Screening in Ovarian Cancer Patients

CATALYST

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

HIPEC

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

N-Plus

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Nudge to Gynecologic Oncology

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer